๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-04-22

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma (NCT01920932)

๐Ÿ”ต Active, Not Recruiting Phase2 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: St. Jude Children's Research Hospital

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Drugs used in chemotherapy, such as etoposide, prednisone, doxorubicin hydrochloride, cyclophosphamide, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells and reduce the need for radiation therapy.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (5 items).

Location: Lucile Packard Children's Hospital Stanford University โ€” Palo Alto, California

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • CD30 negative HL.
  • Has received prior therapy for Hodgkin lymphoma, except as noted above.
  • Inadequate organ function as described above.
  • Inability or unwillingness of research participant or legal guardian / representative to give written informed consent.

๐Ÿ” Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

๐Ÿ“ All Participating Trial Locations (6 Sites)

  • Lucile Packard Children's Hospital Stanford University โ€” Palo Alto, California
  • St. Jude Midwest Affiliate โ€” Peoria, Illinois
  • Maine Children's Cancer Program (MCCP) โ€” Scarborough, Maine
  • Massachusetts General Hospital Cancer Center โ€” Boston, Massachusetts
  • Dana-Farber Harvard Cancer Center โ€” Boston, Massachusetts
  • St. Jude Children's Research Hospital โ€” Memphis, Tennessee

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
๐Ÿ›๏ธ View Official NIH Record โ†—